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Abstract 
Animal studies suggest that N-methyl-D-aspartate receptor (NMDAR) dependent signalling in limbic 
and prefrontal regions is critically involved in both cognitive and emotional functions. In humans, 
ketamine-induced transient, and disorder associated chronic NMDAR hypofunction (i.e. in 
schizophrenia) has been associated with deficient performance in the domains of memory and 
higher-order emotional functioning, as well as altered neural activity in the underlying limbic-
prefrontal circuits. To model the effects of NMDAR hypofunction on the integration of emotion and 
cognition the present pharmacological fMRI study applied the NMDAR antagonist ketamine (target 
plasma level = 100ng/ml) to 21 healthy volunteers in a within-subject placebo-controlled crossover 
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design during encoding of neutral, positive and negative pictures. Our results show that irrespective 
of emotion, ketamine suppressed parahippocampal and medial prefrontal activity. In contrast, 
ketamine selectively increased amygdala and orbitofrontal activity during successful encoding of 
negative stimuli. On the network level ketamine generally increased medial prefrontal-
parahippocampal coupling while specifically decreasing amygdala-orbitofrontal interplay during 
encoding of negative stimuli. On the behavioural level, ketamine produced generally decreased 
memory performance and abolished the emotional enhancement of memory after a wash-out 
period of 5 days. The present findings suggest that ketamine produces general as well as valence-
specific effects during emotional memory formation. The pattern partly overlaps with alterations 
previously observed in patients with schizophrenia.  
 
 
Key words 
NMDAR, limbic cortex, orbitofrontal cortex, schizophrenia, emotion regulation   
 
1. Introduction  
 
N-methyl-D-aspartate receptors (NMDAR) are widely distributed throughout the brain, with 
particular high densities in frontal and limbic regions involved in cognition, including memory 
processing, and emotion (Fletcher and Henson, 2001; Lepage et al., 1998; Walter et al., 2014; Riedel 
et al., 2003; Phan et al., 2002; Etkin et al., 2011). Animal studies consistently revealed that 
experimental application of competitive or non-competitive NMDAR antagonists transiently disrupts 
memory performance (Puma et al., 1998), with particularly pronounced effects when the drug 
interfered with the acquisition of novel information (Newcomer et al., 2000). In recent years 
pharmacological studies in humans have increasingly employed the non-competitive NMDAR 
antagonist ketamine as a translational model to explore the behavioural and neural effects of 
NMDAR-hypofunction (Stone et al., 2009). The observed detrimental effects of ketamine 
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administration on cognitive performance, including memory (Krystal et al., 1994, Newcomer et al., 
1999, Hetem et al., 2000), closely resemble those observed in animal models. Results from 
functional MRI (fMRI) further suggest that ketamine administration in humans influences, and 
interferes with, the underlying memory-related neural circuitry (Honey et al., 2005; Wong et al., 
2016, Grimm et al., 2015).  
 
Recent animal work emphasizes an involvement of NMDAR-dependent signalling in medial 
prefrontal cortex (mPFC) and amygdala during emotional processing and emotion-cognition 
interactions, including emotional learning (Vieira et al., 2015; Hegoburu et al., 2014; Masneuf et al., 
2014). These are in line  with studies in humans which revealed emotion-specific disruptions during 
facial emotion encoding and recognition, as well as altered amygdala and prefrontal functioning 
following ketamine-induced NMDAR blockade (Ebert et al., 2012; Schmidt et al., 2013, Abel et al., 
2003). The potential involvement of the NMDAR in emotion processing is further substantiated by 
the rapid antidepressant effect of single-dose administrations of ketamine in treatment-resistant 
depression (Aan Het Rot et al., 2012; Zarate et al., 2006).  
 
In addition to its potential involvement in depression, altered NMDAR-signalling has been suggested 
to play a critical role in the pathophysiology of schizophrenia (Krystal et al., 2003). Initial 
observations that NMDAR antagonists, including ketamine, produce psychotomimetic symptoms 
and cognitive disruptions similar to those observed in schizophrenia patients (Krystal et al., 1994; 
Corlett et al., 2011) resulted in a NMDAR hypofunction model of schizophrenia (e.g. Jentsch and 
Roth 1999). Schizophrenia is a complex neuropsychiatric disorder characterized by marked 
impairments in cognitive and emotional domains (Bleuler, 1950). Neuropsychological studies 
consistently revealed cognitive (Heinrichs and Zakzanis, 1998; Reichenberg and Harvey, 2007), 
particularly memory (Mesholam-Gately et al., 2009), deficits in patients with schizophrenia. 
Dysfunctions in the emotional domain have gained increasing attention during the last years, with 
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meta-analytic data suggesting marked impairments in higher-order emotional processing in 
schizophrenia patients (Marwick and Hall, 2008; McCleery et al., 2015). In contrast, findings 
regarding disruptions in basic emotional processing remain less clear. Whereas some studies 
revealed that schizophrenia patients retrospectively report decreased levels of positive and 
increased levels of negative emotional experience (Cohen and Minor, 2008; Blanchard et al., 1998), 
immediate emotional experience have been found to be intact (Aleman and Kahn, 2005; Kring and 
Moran, 2008). These contradictory findings might point to a disintegration of emotion and cognition 
in schizophrenia, where immediate emotional experiences are intact, however, the impact of 
emotional experience on memory is disrupted.  
 
Current concepts of emotion-memory interactions hold that memory for emotional information is 
enhanced relative to neutral information (Dolcos et al., 2004; La Bar and Cabeza, 2006). 
Neuroimaging studies on encoding of neutral (Kim, 2011) and emotional information (Murty et al., 
2010; Hermans et al., 2014) indicate a high overlap between NMDAR-rich regions and the emotional 
memory networks, with successful encoding being associated with increased activity in 
hippocampal, fusiform and prefrontal regions (subsequent memory effect, SM), and the 
enhancement of emotional relative to neutral information being dependent on the hippocampal 
formation and the amygdala (emotional subsequent memory effect, ESM). A number of studies 
examined the ESM in schizophrenia patients to specifically probe the disintegration of emotion and 
cognition (Herbener, 2008). Most ESM studies observed normal emotional experience during 
encoding in schizophrenia patients (Lakis et al., 2011; Herbener et al., 2007; Hall et al., 2007), 
however, with regard to the specificity of impairments in the domain of the emotional subsequent 
memory effect findings remained inconsistent ranging from unspecific impairments (Lakis et al., 
2011; Hall et al., 2007) to highly selective impairments for positive information only (Herbener et al., 
2007).  
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Based on accumulating evidence for a critical role of NMDAR-signaling in both cognition and 
emotion, initial pharmacological fMRI evidence for emotion-specific effects of ketamine-induced 
transient NMDAR hypofunctioning (Abel et al., 2003; Scheidegger et al., 2016) and findings in 
schizophrenia patients with a putative NMDAR hypofunctioining it is hypothesized that 
experimentally induced NMDAR hypofunctioning in healthy subjects might (1) disrupt emotion-
cognition interaction during emotional memory formation, and (2) produce a pattern of general as 
well as emotion-specific neural effects. To this end, the present randomized within-subject placebo-
controlled crossover design combined the application of ketamine versus placebo during emotional 
memory formation with fMRI. To control for (sub-)acute effects of ketamine on recognition 
participants underwent a 5-day washout period before the assessment of emotional memory 
performance. Based on previous findings we expected that ketamine administration would abolish 
the emotional enhancement of memory and suppress amygdala-hippocampal activity during 
emotional memory formation mirroring disintegration of emotional experience on memory 
formation.  
 
 
2. Material and methods 
 
2.1 Participants  
Healthy, non-smoking, right-handed male volunteers with normal verbal intelligence as assessed by 
the Mehrfachwahl-Wortschatz-Intelligenztest (MWT-b, Lehrl, 2005) were recruited at the University 
of Bonn, Germany. Prior to study inclusion all participants were thoroughly screened for exclusion 
criteria. Study-specific exclusion criteria included MRI contraindications, current or previous history 
of axis I disorders according to the DSM IV criteria (assessed by the MINI, Ackenheim et al., 1999), 
diagnosis of psychotic disorders among first degree relatives, neurological or cardiovascular 
disorders, history of illicit drug use, head-injuries, body mass index (BMI) < 19 or > 25, regular use of 
medication, use of psychoactive substances in the 7 days prior to the experiment (validated via urine 
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sample and enzyme-multiplied immunoassay, nal von minden GmbH, Regensburg, Germany). 
Participants were instructed to maintain their regular sleep and wake cycles before the experiment, 
and to abstain from food intake during the 6 hours preceding treatment. Participants received 
monetary compensation for study participation. The study had ethical approval of the local ethics 
committee at the University of Bonn and was in accordance with the latest revision of the 
Declaration of Helsinki. All participants provided written informed consent before study inclusion.  
 
From a total of 43 volunteers assessed for study eligibility 29 met the study-specific criteria and were 
enrolled in the study. Participants data were excluded from all further analyses in case participants 
failed to attend the second pharmaco-fMRI assessment (n=2), were not able to adhere to the 5-day 
post pharmaco-fMRI memory assessment interval (n=2), misunderstood the instructions (n=1), or 
showed head-movements >3mm during fMRI (ketamine, 2; placebo, 1). The final study sample 
(n=21) had an average age of 25.1 (±3.5) years, 17.5 (±2.8) years of education, and an estimated 
verbal IQ of 111 (±7.4).  
 
2.2 Study protocols  
Effect of ketamine on emotional memory formation and subsequent recognition performance were 
assessed by embedding a pharmacological fMRI (pharmaco-fMRI) experiment in a double-blind 
randomized within-subject placebo-controlled crossover design. To control for order effects the 
order of ketamine and placebo administration was counterbalanced across participants, pharmaco-
fMRI assessments were separated by  7 days and administered at the same time of the day (<1.5h 
difference). Immediately before the start of the pharmaco-fMRI experiments subjects were screened 
by an experienced anaesthesiologist (C.N.), the anaesthesiologist also continuously monitored the 
vital signs of the participants during pharmaco-fMRI using an MRI-compatible pulse oximeter and a 
supervised post-scanning period. In line with previous ketamine-induced model psychosis 
experiments (Schmechtig et al., 2013) participants received either racemic ketamine (Ketamin-
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Ratiopharm 500, injection solution, Ratiopharm©, Ulm, Germany) or placebo (0.9% saline solution, 
Ratiopharm©, Ulm, Germany) via identical 1-hour application protocols by means of a computer-
controlled infusion pump (Graseby 3500 infusion pump, Smith Medical Int. Ltd, Luton, UK). Ketamine 
was administered as a 2 mg/ml solution with a constant target plasma level of 100 ng/ml, 
application protocols were individually adopted to the weight and height of each participant. The 
infusion protocol adhered a previously validated continuous bolus infusion protocol based on a 
three compartment model (Domino et al., 1982; Schmechtig et al., 2013) and was implemented 
using the STANPUMP software (Steven L. Shafer, M.D., Anesthesiology Service (112A), PAVAMC, 
Palo Alto, CA, USA). Ketamine reaches peak plasma concentrations within a minute when 
administered intravenously (Domino et al., 1984). Ketamine has a high lipid solubility and low 
plasma protein binding (12%), which facilitates rapid transfer across the blood–brain barrier. 
Initially, it is distributed to highly perfused tissues, including the brain (Haas & Harper, 1992). 
Terminal elimination half-life ranges from 100-200 minutes. To evaluate the ketamine blood-levels 
and confirm treatment, blood samples were drawn from the non-infusion arm before, during, and 
after infusion of both, placebo and ketamine. Plasma-samples were stored at -80°C and ng/ml, 
concentrations were analysed by an independent biomedical laboratory (Schottdorf MVZ GmbH, 
Augsburg, Germany).  
 
Experimental paradigms started 5 minutes after the infusion, the present paradigm started 30 
minutes after infusion onset and was preceded by a non-emotional eye movement paradigm 
(Steffens et al., 2016). To control for potential confounding effects of ketamine on cardiovascular 
activity, heart rate was recorded from the MRI-compatible pulse oximeter at the start of the 
experimental paradigm, and +15 and +30 minutes relative to the start of the experiment. To control 
for potential confounding effects of treatment on attention, sustained attention was assessed during 
infusion of both, ketamine and placebo, using a subset of the validated d2 test of attention 
(Brickenkamp, 2002). To evaluate the psychotomimetic properties of ketamine administration 
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participants completed the Psychotomimetic States Inventory (PSI) (Mason et al., 2008) before 
during and after infusion of ketamine and placebo. To evaluate the effects of treatment on the ESM 
effect recognition memory performance was assessed after a 5-day washout period. In order to 
control for circadian effects on memory performance assessment times were intra-individually 
matched.  
 
2.3 Experimental paradigm  
The event-related ESM paradigm was adopted from a previous pharmaco-fMRI study (Striepens et 
al., 2012). Briefly, during each fMRI assessment neutral, positive and negative pictorial stimuli from 
the standardized IAPS database (Lang et al., 2005) were displayed. To control for repetition effects 
two matched stimuli sets with 30 pictures per condition were used (mean valence (SD): Set A, 
negative 2.8 (0.6), positive 7.1 (0.5), neutral 5.1 (0.3); Set B, negative 2.8 (0.6), positive 6.9 (0.6), 
neutral 5.2 (0.5); mean arousal (SD): Set A, negative 5.4 (0.9), POS 5.5 (1.2), neutral 3.6 (0.7); Set B, 
negative 5.4 (0.9), positive 5.5 (1.2), neutral 3.4 (0.6), all p > 0.12, paired t-test comparing valence 
and arousal ratings between sets) and balanced across treatments. Pictures were presented 3 
seconds for encoding, followed by validated ratings scales for arousal and valence to assess 
immediate emotional experience during treatment (self-assessment manikin, scales ranging from 1 
(minimum) to 9 (maximum), Bradley and Lang, 1994) and a jittered interstimulus interval ranging 
from 4-6 seconds. Each rating scale was presented for 3 seconds and the order of rating scales was 
balanced across participants. Before treatment application each participant was familiarized with 
the paradigm during a short training session and was informed about the subsequent memory 
assessment. Five days after each scanning session subjects were presented the stimuli shown during 
the previous scanning session randomly intermixed with 20 matched distractors stimuli per 
condition (distractor sets, mean valence (SD): Set A, negative 2.9 (0.6) , positive 7.0 (0.5), neutral 5.2 
(0.5); Set B, negative 2.9 (0.5), positive 7.0 (0.6), neutral 5.0 (0.6); mean arousal (SD): Set A, negative 
5.4 (0.8), positive 5.5 (1.3), neutral 3.4 (0.7); Set B, negative 5.4 (0.8), positive 5.5 (1.3), neutral 3.5 
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(0.8), all p > 0.37, paired t-test). During the forced choice recognition memory test outside of the 
scanner subjects had to indicate via button press whether the stimuli had been shown during the 
preceding scanning session or not.  
 
2.4 MRI data acquisition  
MRI data were acquired at 3 Tesla using a Trio MRI system (Siemens, Erlangen, Germany) equipped 
with a standard 12 channel head coil. Before treatment application a high-resolution T1-weighted 
structural MRI image (TR = 1570ms; TE = 3.42ms; inversion time (TI) = 800ms; flip angle = 15°; FoV = 
256 mm; matrix size = 256 x 256; 160 slices; slice thickness = 1 mm; sequential slice-order with no 
inter-slice gap; voxel size = 1 x 1 x 1) was acquired to exclude subjects with apparent brain 
pathologies and to optimize off-line normalization of functional time-series. Functional MRI time-
series were acquired using a gradient-echo planar image sequence (TR = 2500ms; TE = 30ms; flip 
angle = 90°; FoV = 192mm; matrix size = 64 x 64; 37 slices; slice thickness = 3 mm; sequential slice 
order with interslice gap of 0.3 mm; voxel size = 3 x 3 x 3.3mm). In total 550 whole brain images 
were acquired during each pharmaco-fMRI session.  
 
2.5 Behavioural data analyses  
The pattern of ketamine-induced psychotomimetic effects in the present sample were evaluated by 
means of repeated measures ANOVAS with treatment (ketamine, placebo) and time (before, during, 
after infusion) as within-subject factors. Dependent variables in this analysis were the scale-specific 
ln-transformed values from the Psychotomimetic States Inventory (PSI) (Mason et al., 2008) that 
were assessed before during and after infusion of ketamine and placebo. Post-hoc tests for the PSI 
scales were Bonferroni adjusted with a p < 0.01 considered significant. Effects on heart rate were 
assessed by means of a repeated measures ANOVA with treatment (placebo, ketamine) and time 
(recorded at the start of the experiment, after 15 min, after 30 min) and heart rate as dependent 
variable. Emotional ratings during encoding were analysed using repeated measures ANOVAs with 
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treatment (ketamine, placebo) and valence (negative, neutral, positive) as within-subject factors and 
arousal or valence ratings as dependent variable. In line with previous studies (e.g. Richardson et al., 
2004; Hall et al., 2007) recognition memory was examined using an accuracy measure that accounts 
for the rate of correctly recognized items (hit rate) as well as the rate of incorrectly identified 
distractor stimuli (false alarm rate) defined as difference between the hit rate and the false alarm 
rate. Accuracy measures were separately calculated for each emotional valence (negative, neutral, 
positive) and each treatment condition (ketamine, placebo). Emotional valence specific effects of 
ketamine on recognition memory were examined by means of a repeated measures ANOVAs with 
treatment (ketamine, placebo) and valence (negative, neutral, positive) as within-subject factors and 
recognition accuracy as dependent variable. In line with previous emotional subsequent memory 
studies (Rasch et al., 2009) emotional enhancement of memory was further explored by calculating 
individual differences between the rate of correctly recognized stimuli for each emotional condition 
(positive, negative) and the neutral condition after each treatment application. Based on our a priori 
hypothesis that ketamine would abolish the enhancement of emotional relative to neutral 
information this hypothesis was tested one-sided, with p < 0.05 considered significant.   
 
2.6 fMRI data analysis 
fMRI data were preprocessed and analysed using SPM8 (Welcome Trust Centre for Neuroimaging, 
London, UK). Preprocessing was carried out using standardized protocols (see Becker et al., 2013). 
Briefly, after discarding the first 5 images, the time-series were motion corrected, co-registered to 
the T1-image, spatially normalized to the Montreal Neurological Institute (MNI) standard space by 
means of a two-step procedure implementing segmentation of the T1-image and application of the 
resulting transformation parameters to the functional time-series SPM8 (resampled at a 3x3x3mm 
resolution), and smoothed using a full width half maximum (FWHM) 8mm Gaussian kernel. On the 
first level valence-specific (negative, neutral, positive) regressors were modelled separately for the 
later successfully remembered and forgotten items. To further control for motor-related activity and 
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movement related artefacts, valence/arousal rating-periods and head motion parameters were 
included in the design matrix as additional regressors. In line with the design and aim of the present 
study the second level analysis focused on main and interaction effects of ketamine on: (1) 
subsequent memory effect (SM): to determine regions involved in memory formation by analysing 
differences between subsequently remembered vs. subsequently forgotten events (‘difference due 
to memory’, Dm, effect); (2) emotional encoding (EE): to determine regions differentially involved in 
successful encoding of negative, neutral and positive stimuli (to control for effects of ketamine on 
depth of processing during encoding (Honey et al., 2013) and biasing effects of the hypothesized 
effects of ketamine on memory performance (Honey et al., 2004) only subsequently remembered 
items were included in this analysis), (3) emotional subsequent memory (ESM): to determine regions 
involved in emotion enhanced memory formation by identifying regions that show a larger Dm 
effect for emotional than neutral events (Dmemotional > Dmneutral). Given that the mean number of 
valence-specific forgotten items was rather low in the present sample valence-specific ESM were 
analysed by comparing the valence-specific subsequently recognized stimuli with all subsequently 
forgotten stimuli. Based on meta-analyses of studies on successful encoding (Kim, 2011), emotional 
processing (Phan et al., 2002; Etkin et al., 2011), and emotional memory formation (Murty et al., 
2010) fusiform gyrus, amygdala, hippocampal formation, anterior cingulate cortex/medial prefrontal 
cortex, and the orbitofrontal cortex were defined as a priori regions of interest (ROIs). Bilateral 
structural masks were defined using a standardized brain atlas (Automated Anatomical Labelling, 
AAL, Tzourio-Mazoyer et al., 2002), results were thresholded at p < 0.05, corrected for multiple 
comparisons by means of family-wise error (FWE) correction. In addition, ketamine effects on the 
network level were examined using a generalized form of context-dependent psychophysiological 
interaction (gPPI) analysis (McLaren et al., 2012). Seed-regions for the analysis of functional 
connectivity were 6-mm spheres centred at the maximum t-value of the ketamine effects as 
determined by the BOLD level analyses of the emotional encoding (EE) and emotional subsequent 
memory (ESM) effects. Effects in target regions were examined within the same structural masks as 
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used for the BOLD level analysis and thresholded at p < 0.05 FWE-corrected. To further explore 
treatment effects on BOLD level and functional connectivity parameter estimates were extracted 
from the underlying contrast maps by means of 6mm spheres centred at the location of the 
maximum t-value using marsbar (Brett et al., 2002). 
 
 
3. Results 
3.1 Ketamine blood levels, psychotomimetic states, pulse and attention  
On average participants received 0.45 mg/kg ketamine (±0.02, range 0.41-0.50) during the 1h 
scanning protocol. Due to technical difficulties detailed ketamine levels could not be obtained from 
all blood samples. For the n = 16 samples that allowed detailed analysis of ketamine during infusion, 
ketamine mean plasma level was 89.76 ±14.32 ng/ml (range 54.30-114.00 ng/ml). Blood samples 
drawn 1h after the ketamine infusion indicated that ketamine plasma levels significantly decreased 
during the post scanning period (42.38 ±14.65 ng/ml, t(15) = 9.85, p < 0.001, paired t-test). An 
additional application check for the entire sample revealed that in all blood samples drawn during 
placebo infusion ketamine concentration was <10 ng/ml plasma in all pre-, during- and post-infusion 
samples. Ketamine concentration was <10ng/ml plasma in all pre-ketamine infusion samples and 
>10 ng/ml in all samples collected during ketamine infusion. Examination of ln-transformed PSI 
scores revealed that ketamine increased values on the PSI subscales of Delusional Thinking (F(1,20) = 
4.41, p = 0.049) and Perceptual Distortion (F(1,20) = 18.15, p < 0.001) across application stages. 
Increases in interaction with application stage were found for the subscales Delusional Thinking 
(F(2,40) = 5.12, p = 0.010), Perceptual Distortion, (F(2,40) = 5.77, p < 0.001), and Cognitive 
Disorganization (F(2,40) = 6.22, p = 0.004). Compared to placebo, ketamine increased the self-reported 
psychotomimetic states on these subscales specifically during infusion (Delusional thinking, t(20) = 
3.12, p = 0.005; Perceptual Distortion, t(20) = 6.06, p < 0.001; Cognitive Disorganization, t(20) = 3.08, p 
= 0.006). Examining the heart rate over the course of the experiment revealed no main effect of 
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assessment time or interaction effects between assessment time and treatment (both p > 0.22), 
however a significant main effect of treatment (F(1,20) = 41.38, p < 0.001) indicating that ketamine 
significantly increased heart rate (mean placebo, 68.11 ±7.14; ketamine 76.47 ±10.08). Comparison 
of attentional performance during placebo and ketamine did not reveal significant differences in the 
total number of items (placebo, 175.20 ±16.91; ketamine, 173.75 ±16.72) or errors (placebo, 3.3 
±2.70; ketamine 4.2 ±7.26; both p > 0.56, paired t-test) arguing against confounding effects of 
ketamine on basal attentional performance during encoding.  
 
3.2 Effects of ketamine on valence and arousal ratings during encoding  
In line with the standardized arousal ratings from the IAPS database, positive and negative stimuli 
were perceived as more arousing than the neutral stimuli (mean rating neutral 3.46 ± 1.19, negative 
5.41 ± 1.19, positive 5.04 ±1.27, both p < 0.05). As expected, valence ratings differed between the 
emotional categories, with low valence ratings for negative stimuli (2.57 ± 0.42), intermediate 
ratings for neutral stimuli (5.20 ± 0.34), and highest valence ratings for positive stimuli (6.60 ± 0.70). 
Repeated-measures ANOVA with treatment (ketamine, placebo) and stimulus valence (negative, 
neutral, positive) as within-subject variables and arousal ratings during pharmaco-fMRI as 
dependent variable yielded a significant main effect of stimulus valence (F(2,40) = 28.38, p < 0.01) and 
a trend-to-significant treatment x stimulus valence interaction effect (F(2,40) = 2.79, p = 0.074), but no 
main effect of treatment (p = 0.28). An exploratory post-hoc test for the treatment x arousal 
interaction effect by means of a direct comparison between treatment-specific arousal ratings for 
the high-arousal conditions (positive, negative) revealed that ketamine increased arousal for positive 
(placebo 4.85 ± 1.23, ketamine 5.39 ± 1.38, t(20) = -3.142, p = 0.005) but not negative stimuli (placebo 
5.45 ± 1.10, ketamine 5.39 ± 1.48, t(20) = 0.25, p = 0.81). A corresponding repeated-measures ANOVA 
with valence ratings during pharmaco-fMRI as dependent variable yielded a main effect of stimulus 
valence (F(2,40) = 336.63, p < 0.01), but neither main nor interaction effect with treatment reached 
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statistical significance (both p > 0.20), suggesting that ketamine did not affect the perceived valence 
of the stimuli during encoding. 
 
3.3 Effects of ketamine on subsequent memory performance  
Repeated measures ANOVA with accuracy (hit rate – false alarm rate) as dependent variable yielded 
a significant main effect of treatment (F(1,20) = 5.59, p = 0.028) indicating significantly lower accuracy 
following ketamine independent of valence. Neither the main effect of emotion nor the treatment x 
emotion interaction passed the significance threshold (both p > 0.52). Given the low false alarm (7-
13%) rates in the present sample, additional analyses separately assessed effects on false alarm and 
hit rate. Repeated measures ANOVA with false alarm rate at follow-up revealed a significant main 
effect of emotion (F(2,40) = 7.89, p = 0.001), with post-hoc tests indicating that independent of 
treatment false alarm rates were higher for negative compared to neutral (mean false alarm rate in 
percent: neutral 7.14 ±7.38, negative 11.79 ±7.95, p = 0.001) as well as positive compared to neutral 
stimuli (positive 10.24 ±9.58, p = 0.009), whereas false alarm rates for positive and negative stimuli 
did not differ (p = 0.266).  Neither the main effect of treatment nor the treatment x emotion 
interaction reached significance (both p > 0.27). Repeated measures ANOVA with subsequent 
recognition performance (hit rate) as dependent variable revealed a main effect of emotion (F(2,40) = 
5.95, p = 0.019) and treatment (F(1,20) = 6.47, p = 0.005). Post-hoc tests confirmed the memory 
advantage of emotional stimuli as indicated by significantly enhanced recognition performance for 
emotional stimuli compared to neutral stimuli (mean hit rate in percent: neutral 75.15 ± 13.79, 
negative 82.30% ±11.04, positive 78.96 ±9.41). Ketamine administration generally decreased 
recognition performance across emotional conditions (mean hit rate in percent: placebo 81.43 ± 
10.51, ketamine 76.19 ±11.86). Further exploratory analyses of valence-specific decreased memory 
performance using paired t-tests revealed preliminary evidence that ketamine significantly 
decreased recognition of positive stimuli (placebo 81.90% ± 10.19, ketamine 76.03% ± 12.27%; t(20) = 
-2.54, p = 0.009), while relatively sparing recognition performance for neutral and negative stimuli 
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(neutral: placebo 77.46% ± 12.24, ketamine 72.85 ± 16.84; t(20) = -1.92, p = 0.070; negative: placebo 
84.92% ± 14.89; ketamine 79.68% ± 12.19; t(20) = -1.69, p = 0.110).  
 
3.4 Effects of ketamine on emotional enhancement of memory  
Relative to neutral stimuli, recognition memory was significantly enhanced for both, negative and 
positive stimuli following the placebo administration. Relative to neutral pictures, subjects 
recognized on average 7.46% (± 13.07) more negative, and 4.44% (± 10.61) more positive pictures 
after placebo (negative, t(20) = 2.38, p = 0.031; positive, t(20) = 2.22, p = 0.038, paired t-tests). 
Following ketamine administration, subjects recognized significantly more negative than neutral 
pictures (6.83% ±14.54%, t(20) = 4.40, p = 0.036), however ketamine abolished the emotional 
enhancement for positive stimuli (3.17%, ± 13.56%, t(20) = 1.23, p = 0.23). However, a direct 
comparison of the ESM during ketamine versus placebo using repeated measure ANOVA failed to 
reveal significant interaction effects, possibly due to the high interindividual variance in the 
strengths of the emotional memory effect following both placebo as well as ketamine application.  
 
3.5 fMRI findings  
3.5.1 Subsequent memory analysis (SM) 
In line with previous studies and meta-analytic data (Kim, 2011), encoding of subsequently 
successful recognized stimuli was associated with higher activity in the hippocampal formation (T = 
4.92, pFWE < 0.05, maximum t-value at -26/-42/-10, left parahippocampal gyrus, k  = 4) and the 
bilateral fusiform gyrus (left, T = 4.54, maximum t-value at -24/-50/-14, k = 22; right, T = 4.41, 
maximum t-value at 32/-44/-18, k = 3, pFWE < 0.05). No interaction effects with treatment were 
observed for the combined valence conditions including negative, neutral and positive stimuli 
against an unspecific effect of ketamine on the subsequent memory networks. To explore 
associations between neural activity during encoding and subsequent memory performance, 
parameter estimates were extracted from the regions showing higher activity during successful 
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memory formation and correlated with subsequent memory performance. Neither during ketamine 
nor placebo significant associations were observed (p > 0.05).  
 
3.5.2 Differential effects on emotional encoding (EE) 
Examination of the main effect of treatment on successful encoded items revealed significant main 
effects in the right parahippocampal gyrus (T = 5.73, PFWE < 0.05, maximum t-value at 22/-44/-6, k = 
3) and the bilateral mPFC (T = 6.01, maximum t-value at 8/52/40, k = 2; T = 5.78, maximum t-value at 
0/58/28,  k = 6, PFWE < 0.05), indicating that ketamine decreased encoding-related activity in these 
regions irrespective of emotion. Analyses of differential effects of ketamine during successful 
encoding of negative, neutral and positive stimuli revealed emotion x treatment interaction effects 
in the right parahippocampal gyrus (T = 3.89, PFWE < 0.05, maximum t-value at 26/-44/-4, k = 5), left 
amygdala (T = 3.76, PFWE < 0.05, maximum t-value at -24/0/-18, k = 11), and right medial 
orbitofrontal cortex (T = 4.67, PFWE < 0.05, maximum t-value at 10/56/-6, k = 19) (Fig 1a). Extraction 
of individual parameter estimates revealed that ketamine significantly decreased parahippocampal 
activity during successful encoding of neutral and positive (neutral, t = 3.84; positive, t = 6.11, both p 
 0.001, paired t-test), but not negative stimuli (t = 0.72, p = 0.48). In contrast, ketamine increased 
left amygdala and right orbitofrontal activity during successful encoding of negative (t = -3.01, p = 
0.007; t = -3.27, p = 0.004), but not positive or neutral stimuli (neutral, t = -0.18; t = -0.93, positive, t 
= 0.30; t = 1.14 all p > 0.27) (Fig 1b).  
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Figure 1  
 
Figure 1 Title Emotion-specific effects of ketamine during encoding Description During encoding of 
negative, neutral and positive stimuli ketamine produced valence-specific effects in the 
parahippocampal region, the amygdala and the orbitofrontal cortex. (a) Location of the interaction 
effects, (b) extracted parameter estimates showing the direction of the valence-specific effects 
during encoding. Results were obtained using small-volume correction within a priori defined 
structural regions of interest using a peak-level threshold of p < 0.05 FWE-corrected.  
 
3.5.3 Emotional subsequent memory analysis (SEM) 
Examining the emotional enhancement of memory revealed that ketamine modulated the ESM for 
negative events in the left amygdala (T = 4.73, PFWE < 0.05, maximum t-value located at -18/0/-14, k 
= 14). Extraction of parameter estimates revealed that this region displayed comparable activity for 
negative and neutral stimuli during placebo (t = -1.08, p = 0.29), with ketamine producing differential 
encoding-related activity for negative and neutral stimuli (t = 3.89, p = 0.001, paired t-test). This 
modulatory effect was specifically driven by increased amygdala reactivity to negative stimuli during 
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ketamine (NEG, t = -2.36, p = 0.03; NEU, t = 0.85, p = 0.41; paired t-test, Fig 2). In contrast no 
modulatory effects were found for the positive ESM. Associations between ketamine-induced 
increased amygdala activity during encoding of negative stimuli and subsequent memory for 
negative stimuli were further explored using correlational analyses. Neither during ketamine nor 
placebo significant associations were observed (p > 0.05).  
 
Figure 2  
 
Figure 2 Title Ketamine effects on the emotional enhancement of memory networks Description 
Ketamine specifically increased the reactivity of the left amygdala during encoding of negative 
stimuli. Results were obtained using small-volume correction within a priori defined structural 
regions of interest using a peak-level threshold of p < 0.05 FWE-corrected.  
 
 
3.5.4 Effects on the network level  
Functional connectivity analyses of the regions showing differential effects under ketamine versus 
placebo  during emotional encoding (EE) revealed a significant main effect of ketamine on left mPFC-
right hippocampus connectivity (seed centred at 0/58/28; t = 5.15, PFWE < 0.05, maximum t-value 
located at 16/-32/-4, k = 2), indicating that ketamine increased coupling between these regions 
regardless of emotion. A significant valence x treatment effect was found on left amygdala coupling 
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(seed centred at -24/0/-18) with the ipsilateral frontal orbital cortex (T = 3.58, PFWE < 0.05, maximum 
t-value located at -26/46/-8, k = 1). Extraction of parameter estimates from this region revealed that 
ketamine specifically reduced coupling between this regions for negative (t = 2.12, p = 0.046), but 
not for neutral or positive stimuli (NEU, t = -0.22; POS, t = -1.29, both p > 0.22; paired t-tests, Fig 3). 
No significant effects on the interplay of other regions determined by the BOLD level analyses were 
found.  
 
 
 
 
 
 
 
 
 
 
Figure 3  
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Figure 3 Title Emotion-specific effects of ketamine on amygdala functional connectivity Description 
Ketamine specifically decreased coupling of the amygdala with the orbitofrontal region during 
encoding of negative stimuli. Results were obtained using small-volume correction within a priori 
defined structural regions of interest using a peak-level threshold of p < 0.05 FWE-corrected.  
 
 
3.5.5 Associations between effects of ketamine on arousal for positive stimuli and neural activity  
To further explore the neural basis of the observed increased arousal ratings for positive stimuli 
during ketamine a SPM-based multiple regression was performed using individual change-scores for 
arousal ratings for positive stimuli (ketamine > placebo) as variable to predict neural activity changes 
in the corresponding activity contrast (all positive stimuli during ketamine > all positive stimuli 
during placebo). Due to the exploratory nature of the analysis a whole-brain analysis was performed 
using a cluster-based threshold of p < 0.05 (FWE-corrected on the cluster level, using an initial 
cluster defining threshold of p < 0.001 as recommended by Woo et al., 2014, and a cluster extent of 
> 150 voxel). This analysis revealed a positive association between ketamine-induced changes in 
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positive arousal ratings and corresponding neural activity in the left amygdala (T = 6.04, PFWE < 0.05, 
maximum t-value located at -18 / -2 / -16, k = 172). Extraction of parameter estimates demonstrated 
that a higher increase in arousal for positive stimuli was accompanied by a higher increase in the left 
amygdala reactivity to positive stimuli (Fig. 4). Examining the corresponding associations for the 
negative and neutral condition did not reveal significant associations, indicating valence-specific 
effects of ketamine on amygdala activity.  
Figure 4  
 
Figure 4 Title Associations between arousal ratings for positive stimuli and amygdala reactivity 
Description An exploratory whole-brain analysis revealed associations between the strengths of 
ketamine-induced changes in arousal for positive stimuli and increased activity in the left amygdala. 
Results were obtained using a whole-brain cluster corrected threshold using FWE-cluster correction 
with p < 0.05 and a cluster extent of 150 voxels.  
 
3.5.6 Associations between effects on heart rate and BOLD activity  
Given ketamine increased the heart rate we used an additional exploratory analysis to examine 
whether the individual changes in heart rate were associated with altered neural activity on the 
whole brain level using a sensitive uncorrected threshold of p < 0.001 (k >5). A positive associations 
was found with activity in the right postcentral gyrus (56 / -16 / 12, k = 11) and the right superior 
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temporal gyrus (56 / -2 / -2, k = 6) across valence conditions. Importantly these regions did not 
overlap with the regions of interest used to determine effects during emotional encoding.  
 
4. Discussion 
The present experiment did not reveal strong evidence for altered emotional experience during 
ketamine administration. In line with previous behavioural studies (Krystal et al., 1994, Newcomer et 
al., 1999, Hetem et al., 2000) ketamine produced generally decreased subsequent memory 
performance, and an exploratory analysis revealed preliminary evidence of less severe memory 
impairments and intact emotional enhancement for negative information. Irrespective of emotional 
valence ketamine suppressed para-hippocampal and mPFC activity in the context of increased mPFC-
hippocampal coupling during successful encoding. Analysis of valence-specific effects of ketamine 
revealed suppressed parahippocampal activity during encoding of neutral and positive stimuli, as 
well as increased amygdala and orbitofrontal activity during encoding of negative ones.  Specifically 
examining the neural effects of emotion-facilitated memory further revealed that ketamine 
specifically increased amygdala reactivity to negative stimuli.  
 
4.1 Valence-unspecific effects of ketamine 
Despite a lack of pronounced effects of ketamine on emotional experience during encoding, 
ketamine administration produced robust effects on emotional encoding related neural activity, 
both on a general processing, as well as a valence-specific level. More specifically, ketamine-
administration was accompanied by an valence-independent suppression of right parahippocampal 
and bilateral mPFC activity during successful emotional encoding. The hippocampal formation 
contributes fundamentally to successful memory encoding (Kim et al., 2011), with intact 
parahippocampal gyrus functioning being specifically related to successful delayed recall of non-
verbal visual material (Koehler et al., 1999), and persisting activity in this region being predictive of 
long-term encoding success (Schon et al., 2004). In line with the consistently observed impaired 
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memory performance in schizophrenia patients (Mesholam-Gately et al., 2009), previous 
neuroimaging studies in schizophrenia patients and at-risk populations repeatedly revealed 
decreased encoding-related activity in the hippocampal formation. In particular decreased 
parahippocampal activity during encoding of neutral visual and verbal stimuli has been associated 
with the strengths of memory impairments in schizophrenia patients as well as their first degree 
relatives and, thus, has been suggested to represent a potential intermediate biological phenotype 
related to an increased risk for schizophrenia (Rasetti et al., 2014, Thermenos et al, 2007; Di Giorgio 
et al., 2013).  
 
The mPFC plays a critical role in both emotional experience as well as emotion regulation, including 
effortful as well as automatic emotion regulation via down-regulation of limbic regions, in particular 
the amygdala (Buhl et al., 2014; Etkin et al., 2011, Kober et al., 2008). Meta-analytic data indicates 
that the mPFC is not per se engaged in successful encoding of neutral or emotional material (Kim et 
al., 2011; Murty et al., 2010) and previous studies employing cognitive paradigms with neutral 
stimuli mostly observed modulatory effects of ketamine in prefrontal regions with stronger 
engagement in cognitive processes, particularly dorsolateral regions (Honey et al., 2004; 2005; 
Anticevic et al., 2012), suggesting that the observed emotion-independent decrease might rather be 
associated to emotional than cognitive processing. Schizophrenia patients show marked 
impairments in functional domains that strongly rely on the mPFC, including emotion perception and 
regulation (Savla et al., 2013; O’Driscoll et al., 2014) and concomitantly attenuated activity in this 
region (Taylor et al., 2012; Zilverstand et al., 2016). During ketamine administration the generally 
decreased activity in the mPFC was accompanied by increased coupling of the mPFC with the 
hippocampus. In addition to its critical involvement in memory processing, the hippocampus 
strongly interacts with the amygdala during emotion processing (Murty et al., 2010; Kim et al., 2011, 
Fusar-Poli et al., 2009) and both regions share functional connections with the mPFC (Amft et al., 
2015) suggesting that ketamine-induced decreased emotion-regulation in the mPFC might be 
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accompanied by stronger engagement of the hippocampus in emotional processing and in turn 
disrupts successful memory formation. In addition, hippocampal-mPFC interactions have been 
suggested crucial for integrating new memory into pre-existing knowledge networks (Preston and 
Eichenbaum, 2013; van Kesteren et al., 2012), with increased coupling associated to encoding 
success (Schlichting and Preston, 2015). Thus, increased coupling might represent an (unsuccessful) 
attempt to compensate for suppressed parahippocampal engagement in memory formation during 
ketamine administration, by means of integrating the new information with pre-existing knowledge 
representations. 
 
4.2 Valence-specific effects of ketamine   
In addition to valence-independent effects, ketamine produced a pattern of valence-specific effects 
in the right parahippocampus, left amygdala and right orbitofrontal cortex. In line with the 
pronounced impaired recognition performance for neutral and positive material, parahippocampal 
activity was specifically suppressed during ketamine for these emotions, yet normal during encoding 
of negative material. In contrast, ketamine produced increased activity in the amygdala and 
orbitofrontal cortex specifically during encoding of negative material. Previous studies on emotional 
encoding in healthy individuals revealed increased amygdala activity for emotional, particularly 
negative stimuli (Canli et al., 2000; Fusar-Poli et al., 2009), that has been associated with enhanced 
long-term recognition memory (Hamann et al., 1999; Herbener et al., 2007). In healthy subjects 
amygdala reactivity to negative emotional material shows an inverse relationship to prefrontal 
activity, including the mPFC and superior orbital regions, thought to reflect prefrontal top-down 
emotion regulation of the amygdala (Buhl et al., 2014; Etkin et al., 2011, Kober et al., 2008; Diekhof 
et al., 2011), suggesting that the interaction of valence-independent suppression of mPFC regulatory 
functioning during ketamine with valence-dependent amygdala reactivity, i.e. enhanced activity for 
negative materials, might underlie the observed pattern. The selectively increased amygdala and 
orbitofrontal cortex activity during ketamine for negative material was furthermore accompanied by 
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reduced functional connectivity between the left amygdala and the ipsilateral superior orbitofrontal 
cortex. Similar hypoconnectivity has been previously observed in the context of pathologically 
exaggerated amygdala reactivity for negative material and has been suggested to mirror reduced 
emotion regulation (Hahn et al., 2011). In concordance with the observed pattern during ketamine-
induced NMDAR-hypofunctioning, studies on emotional processing in schizophrenia patients 
repeatedly observed valence-dependent hyperactivity of the amygdala in schizophrenia patients 
(Marwick and Hall, 2008; Pankow et al., 2013). Notably, in the present sample ketamine produced 
predominately positive symptoms of schizophrenia, while in schizophrenia patients stronger positive 
symptomatology has been associated with exaggerated amygdala reactivity to negative pictorial 
stimuli (Taylor et al., 2002: Fahim et al., 2005). 
 
The medial orbitofrontal cortex mirrored the valence-specific increased reactivity to negative stimuli 
observed in the amygdala. The medial orbitofrontal cortex shares extensive reciprocal connections 
with the amygdala (Barbas et al., 2007), and both are central to emotional processing, particularly in 
evaluating salience aspects of the environment that guide emotional learning and promote adaptive 
behaviour (Adolphs et al, 1995; Rolls, 1996; Schoenbaum et al., 2011). Moreover, the connectivity of 
both, the amygdala as well as the orbitofrontal cortex includes reciprocal connections with the 
hippocampal formation, including the parahippocampus, and these pathways have been suggested 
to fundamentally contribute to the impact of emotional salience on learning (Cavada et al., 2000). 
Salience signalling and salience driven-learning have been strongly associated with dopaminergic 
signalling (Abraham et al., 2016) and both the amygdala and the orbitofrontal cortex receive 
extensive mesocortical and mesolimbic dopaminergic inputs (Meador-Woodruff et al., 1997). 
Although ketamine at doses similar to the one used in the present study seem not to directly affect 
striatal dopaminergic functioning (Aalto et al., 2002) glutamate-mediated effects on dopaminergic 
functioning might have contributed to the present findings. The salience processing networks, 
particularly the amygdala and to a lesser extend the orbitofrontal cortex, have been proposed to 
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show hyper-reactivity during psychotic states at early stages of schizophrenia as a consequence of 
reduced cortico-accumbens glutamate activity that in turn fails to provide a tonic dopaminergic 
down-regulation of the phasic dopamine system leading to an exaggerated response to potentially 
significant stimuli (Grace et al., 2000; Aleman and Kahn, 2005). The role of dopamine in gating 
amygdala responsivity is further supported by findings on positive associations between measures of 
amygdala dopamine and higher functional activity in response to aversive stimuli in healthy 
individuals (Kienast et al., 2008) as well as recent animal models of schizophrenia that revealed 
disrupted, particularly exaggerated amygdala, dopamine salience signaling that have been proposed 
to underlie enhanced salience signaling in schizophrenia patients (Hernandez et al., 2015).  
 
4.3 Effects of ketamine on arousal for positive stimuli  
Findings from an exploratory post hoc analysis examining valence-specific effects of ketamine on 
arousal revealed preliminary evidence that ketamine increases the perceived arousal for positive 
stimuli during encoding and that the strengths of this effect was associated with higher reactivity of 
the left amygdala to positive stimuli. Across species, the amygdala has been associated with arousal 
processing (Pelletier et al., 2005; McGaugh, 2004). In humans, the association has been 
demonstrated for negative as well as positive stimuli (Costa et al., 2010; Garavan et al., 2001) and 
activity in the amygdala has been shown to increase with higher experienced emotional intensity of 
positive stimuli (Bonnet et al., 2013; Phan et al., 2003). Previous studies have shown an important 
role of the amygdala in reward and appetitive processing (Wassum & Izquierdo, 2015), and in vivo 
optical stimulation of glutamatergic signaling from the amygdala to the nucleus accumbens 
increases reward responses via dopamine dependent receptor mechanisms promoting appetitive 
behavior (Stuber et al., 2011). Overall, this suggests that ketamine-induced modulation of 
glutamate-mediated appetitive processing might have contributed to the increased arousal 
selectively observed for positive stimuli.  
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Despite increasing arousal for positive stimuli during encoding, ketamine impaired the subsequent 
recognition performance for positive stimuli. This observation stands in contrast to the well-
validated enhancement of memory by arousal via amygdala activity, but might be explained in terms 
of valence-specific effects of ketamine on encoding-related parahippocampal activity. Indeed, 
arousal-induced memory enhancement relies on the modulatory influence of the amygdala on 
memory storage processes in other brain regions, particularly the parahippocampus (Kilpatrick and 
Cahill, 2003). Ketamine suppressed emotional memory enhancement and encoding-related 
parahippocampal activity for positive stimuli, whereas memory enhancement and parahippocamal 
activity were preserved for negative stimuli. This might indicate that ketamine-induced suppression 
of parahippocampal activity during positive stimuli led to a failure of the amygdalar signal to 
modulate memory formation in this region.  
 
4.4 Potential relevance for schizophrenia  
The observed normal emotional experience during encoding and overall impairments in subsequent 
memory performance following ketamine administration observed in the present study replicate a 
pattern previously observed in schizophrenia patients. Although ketamine produced a trend for 
increased arousal ratings for positive stimuli, the lack of effects on arousal for negative/neutral 
stimuli, as well as the absence of ketamine effects on perceived valence largely resemble previous 
observations on intact-in-the moment emotional experience in schizophrenia patients (Herbener, 
2008; Horan et al., 2006). Impaired memory encoding of new information is one of the most 
consistently reported cognitive impairments during ketamine administration (Morgan and Curran, 
2006), observed on recall as well as recognition tasks (Honey et al., 2005), and represents an 
enduring core cognitive deficit in schizophrenia  (Heinrichs and Zakzanis, 1998; Mesholam-Gately et 
al., 2009). Additional exploratory analysis revealed preliminary evidence that ketamine produces a 
valence-dependent pattern of impairments on longer-term recognition memory performance, with 
less severe impairments on negative stimuli in the context of intact emotional enhancement for 
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negative information. Two previous studies examining the emotional subsequent memory effect in 
schizophrenia patients after longer consolidation intervals (< 24h) reported - in addition to generally 
impaired memory performance in the schizophrenia patients - greater rates of forgetting of both, 
positive and neutral stimuli than negative stimuli in a sample of long-hospitalized schizophrenia 
patients (Calev and Edelist, 1993), and a lack of emotional memory enhancement of positive, but 
intact enhancement of negative stimuli in a sample of stable-medicated schizophrenia patients 
(Herbener et al., 2007). However, given the preliminary nature of the emotion-specific behavioural 
effects of ketamine conclusions in this regard need to be drawn with caution.  
 
4.5 Limitations  
Some limitations of the present experiment need to be carefully considered. (1) Ketamine increased 
the heart rate which might have affected the BOLD response. Although the fMRI paradigm included 
a low-level baseline that might partly control for confounding effects, a regional- and valence-
specific pattern of neural effects was observed and an additional exploratory analysis did not reveal 
strong associations between changes in heart rate and BOLD activity, we cannot completely rule out 
potential confounding effects of cardiovascular effects of ketamine on the present results, (2) 
although the psychotomimetic effects of ketamine validate the ketamine model psychosis approach 
we cannot completely rule out that the subjective effects of ketamine might have interfered with 
blinding of the participants, (3) ketamine acts primarily as a non-competitive antagonist of the 
NMDAR, and this action accounts for most of the analgesic, amnestic and psychotomimetic effects 
of ketamine (Kohrs and Durieux, 1998). However, ketamine interacts with multiple binding sites, 
including dopaminergic D2 receptor sites, muscarinic and opiod receptors, although the later might 
only show relevant effects at higher doses (Hirota et al., 1999).  
 
Conclusion  
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Together, our findings indicate general as well as valence-specific neural effects of ketamine during 
successful encoding in memory and emotion processing core regions in the context of normal 
emotional experience during encoding and generally decreased subsequent memory performance 
after a wash-out period of 5-days. Preliminary evidence suggests that subsequent recognition 
performance and emotional enhancement for negative material might be less disrupted by ketamine 
administration during encoding.  
 
 
Funding  
This work was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft, 
DFG, grant numbers ET 31/2-1 to U.E.; BE 5465/2-1 to B.B.; and HU 1302/4-1 to R.H.) 
 
Acknowledgements 
All authors have approved the final version of the manuscript. The authors declare no conflict of 
interest. The authors thank Paul Jung and Inken Salhofen for excellent technical support.  
 
References  
Aalto, S., Hirvonen, J., Kajander, J., Scheinin, H., Någren, K., Vilkman, H., Gustafsson, L., Syvälahti, E., 
Hietala, J., 2002. Ketamine does not decrease striatal dopamine D2 receptor binding in man. 
Psychopharmacology 164 (4), 401-406. 
Aan Het Rot, M., Zarate, C.A., Charney, D.S., Mathew, S.J., 2012. Ketamine for depression: where do 
we go from here? Biol Psychiatry 72 (7), 537-547.  
Abel, K.M., Allin, M.P.G., Kucharzka-Pietura, K., David, A., Andrew, C., Williams, S., Brammer, M.J., 
Philips, M.L., 2003. Ketamine alters neural processing of facial emotion recognition in healthy men: 
an fMRI study. Neuroreport 14 (3), 387-391.  
Abraham, A., Neve, K., Lattal, K., 2016. Activation of D1/5 Dopamine Receptors: A Common 
Mechanism for Enhancing Extinction of Fear and Reward-Seeking Behaviors. Neuropsychopharmacol 
41 (8), 2072-2081. 
Ackenheil, M., Stotz-Ingenlath, G., Dietz-Bauer, R., Vossen, A., 1999. MINI Mini International 
Neuropsychiatric Interview, German Version 5.0. 0 DSM IV. Psychiatrische Universitätsklinik 
München, Germany. 
 
 
30 
Adolphs, R., Tranel, D., Damasio, H., Damasio, A.R., 1995. Fear and the human amygdala. J Neurosci 
15 (9), 5879-5891. 
Aleman, A., Kahn, R.S., 2005. Strange feelings: do amygdala abnormalities dysregulate the emotional 
brain in schizophrenia? Prog in Neurobiol 77 (5), 283-298. 
Amft, M., Bzok, D., Laird, A.R., Fox, P.T., Schilbach, L., Eickhoff, S.B., 2015. Definition and 
characterization of an extended social-affective default network. Brain Struct Funct 220 (2), 1031-
1049.  
Anticevic, A., Gancsos, M., Murray, J.D., Repovs, G., Driesen, N.R., Ennis, D.J., Niciu, M.J., Morgan, 
P.T., Surti, T.S., Bloch, H.M., et al. 2012. NMDA receptor function in large-scale anti-correlated neural 
systems with implications for cognition and schizophrenia. Proc Natl Acad Sci USA 109 (41), 16720-
16725. 
Barbas, H., 2007. Flow of information for emotions through temporal and orbitofrontal pathways. J 
Anat 211 (2), 237-249. 
Becker, B., Androsch, L., Jahn, R.T., Alich, T., Striepens, N., Markett, S., Maier, W., Hurlemann, R., 
2013. Inferior frontal gyrus preserves working memory and emotional learning under conditions of 
impaired noradrenergic signaling. Front Behav Neurosci 7, 197. 
Blanchard, J.J., Mueser, K.T., Bellack, A.S., 1998. Anhedonia, positive and negative affect, and social 
functioning in schizophrenia. Schizophr Bull 24 (3), 413-424. 
Bleuler, E., 1950. Dementia Praecox or the Group of Schizophrenias. New York: International 
Universities Press.  
Bonnet, L., Comte, A., Tatu, L., Millot, J.L., Moulin, T., Medeiros de Bustos, E., 2015. The role of the 
amygdala in the perception of positive emotions: an “intensity detector”. Front Behav Neurosci 9, 
178. 
Bradley, M.M., Lang, P.J., 1994. Measuring emotion: the self-assessment manikin and the semantic 
differential. J Behav Ther Exp Psychiatry 25 (1), 49-59. 
Brett, M., Anton, J. L., Valabregue, R., Poline, J.B., 2002. Region of interest analysis using the 
MarsBar toolbox for SPM 99. Neuroimage 16 (2), S497. 
Brickenkamp, R., 2002. Test d2: Aufmerksamkeits-Belastungs-Test; Manual: Hogrefe, Verlag für 
Psychologie. 
Buhle, J.T., Silvers, J.A., Wager, T.D., Lopez, R., Onyemekwu, C., Kober, H., Weber, J., Ochsner, K.N., 
2014. Cognitive reappraisal of emotion: a meta-analysis of human neuroimaging studies. Cereb 
Cortex 24 (11), 2981-2990.  
 
 
31 
Calev, A., Edelist, S., 1993. Affect and memory in schizophrenia: negative emotion words are 
forgotten less rapidly than other words by long-hospitalized schizophrenics. Psychopathology 26 (5-
6), 229-235. 
Canli, T., Zhao, Z., Brewer, J., Gabrieli, J.D., Cahill, L., 2000. Event-related activation in the human 
amygdala associates with later memory for individual emotional experience. J Neurosci 20 (19), 
RC99. 
Cavada, C., Tejedor, J., Cruz-Rizzolo, R.J., Reinoso-Suárez, F., 2000. The anatomical connections of 
the macaque monkey orbitofrontal cortex. A review. Cereb Cortex 10 (3), 220-242. 
Cohen, A.S., Minor, K.S., 2010. Emotional experience in patients with schizophrenia revisited: meta-
analysis of laboratory studies. Schizophrenia Bulletin 36 (1), 143-150. 
Corlett, P.R., Honey, G.D., Krystal, J.H., Fletcher, P.C., 2011. Glutamatergic model psychoses: 
prediction error, learning, and inference. Neuropsychopharmacology 36 (1), 294-315. 
Costa, V.D., Lang, P.J., Sabatinelli, D., Versace, F., Bradley, M., 2010. Emotional imagery: assessing 
pleasure and arousal in the Brain’s reward circuitry. Hum Brain Mapp 31 (9), 1446-1457. 
Di Giorgio, A., Gelao, B., Caforio, G., Romano, R., Andriola, I., D'Ambrosio E, Papazacharias A, Elifani 
F, Bianco LL, Taurisano P. 2013. Evidence that hippocampal–parahippocampal dysfunction is related 
to genetic risk for schizophrenia. Psychol Med 43 (8), 1661-1671. 
Diekhof, E.K., Geier, K., Falkai, P., Gruber, O., 2011. Fear is only as deep as the mind allows: a 
coordinate-based meta-analysis of neuroimaging studies on the regulation of negative affect. 
Neuroimage 58 (1), 275-285.  
Dolcos, F., LaBar, K.S., Cabeza, R., 2004. Interaction between the amygdala and the medial temporal 
lobe memory system predicts better memory for emotional events. Neuron 42 (5), 855-863. 
Domino, E.F., Domino, S.E., Smith, R.E., 1984. Ketamine kinetics in unpremedicated and diazepam-
premedicated subjects. Clin Pharmacol Ther 36 (5), 645-653. 
Domino, E.F., Zsigmond, E.K., Domino, L.E., Domino, K.E., Kothary, S.P., Dominof, S.E., 1982. Plasma 
levels of ketamine and two of its metabolites in surgical patients using a gas chromatographic mass 
fragmentographic assay. Anesth Analg 61 (2), 87-92. 
Ebert, A., Haussleiter, I.S., Juckel, G., Bruene, M., Roser, P., 2012. Impaired facial emotion 
recognition in a ketamine model of psychosis. Psychiatry Res 200 (2-3), 724-727.  
Etkin, A., Egner, T., Kalisch, R., 2011. Emotional processing in anterior cingulate and medial 
prefrontal cortex. Trends Cogn Sci 15 (2), 85-93. 
Fahim, C., Stip, E., Mancini-Marïe, A., Mensour, B., Boulay, L.J., Leroux, J-M., Beaudoin, G., 
Bourgouin, P., Beauregard, M., 2005. Brain activity during emotionally negative pictures in 
schizophrenia with and without flat affect: an fMRI study. Psychiatry Res 140 (1), 1-15. 
 
 
32 
Fletcher, P.C., Henson, R.N., 2001. Frontal lobes and human memory: insights from functional 
neuroimaging. Brain 124 (Pt 5), 849-881. 
Fusar-Poli, P., Placentino, A., Carletti, F., Landi, P., Allen, P., Surguladze, S., Benedetti, F., Abbamonte, 
M., Gasparotti, R., Barale, F., et al., 2009. Functional atlas of emotional faces processing: a voxel-
based meta-analysis of 105 functional magnetic resonance imaging studies. J Psychiatry Neurosci 34 
(6), 418-432. 
Garavan, H., Pendergrass, J.C., Ross, T.J., Stein, E.A., Risinger, R.C., 2001. Amygdala response to both 
positively and negatively valenced stimuli. Neuroreport 12 (12), 2779-2783. 
Grace, A.A., 2000. Gating of information flow within the limbic system and the pathophysiology of 
schizophrenia. Brain Res Brain Res Rev 31 (2-3), 330-341. 
Grimm, O., Gass, N., Weber-Fahr, W., Sartorius, A., Schenker, E., Spedding, M., Risterucci, C., 
Schweiger, J.I., Boehringer, A., Zang, Z., et al., 2015. Acute ketamine challenge increases resting state 
prefrontal-hippocampal connectivity in both humans and rats. Psychopharmacology 232 (21-22), 
4231-4241. 
Hahn, A., Stein, P., Windischberger, C., Weissenbacher, A., Spindelegger, C., Moser, E., Kasper, S., 
Lanzenberger, R., 2011. Reduced resting-state functional connectivity between amygdala and 
orbitofrontal cortex in social anxiety disorder. Neuroimage 56 (3), 881-889. 
Hall, J., Harris, J.M., McKirdy, J.W., Johnstone, E.C., Lawrie, S.M., 2007. Emotional memory in 
schizophrenia. Neuropsychologia 45 (6), 1152-1159. 
Hamann, S.B., Ely, T.D., Grafton, S.T., Kilts, C.D., 1999. Amygdala activity related to enhanced 
memory for pleasant and aversive stimuli. Nat Neurosci 2 (3), 289-293. 
Hass, D.A., Harper, D.G., 1992. Ketamine: a review of its pharmacologic properties and use in 
ambulatory anesthesia. Anesthesia Progress 39 (3), 61-68. 
Hegoburu, C., Parrot, S., Ferreira, G., Mouly, A.M., 2014. Differential involvement of amygdala 
cortical NMDA receptors activation upon encoding in odor fear memory. Learn Mem 21 (12), 651-
655. 
Heinrichs, R.W., Zakzanis, K.K., 1998. Neurocognitive deficit in schizophrenia: a quantitative review 
of the evidence. Neuropsychology 12 (3), 426-445. 
Herbener, E.S., 2008. Emotional memory in schizophrenia. Schizophr Bull 34 (5), 875-887. 
Herbener, E.S., Rosen, C., Khine, T., Sweeney, J.A., 2007. Failure of positive but not negative 
emotional valence to enhance memory in schizophrenia. Journal Abnorm Psychol 116 (1), 43-55. 
Hermans, E.J., Battaglia, F.P., Atsak, P., de Voogd, L.D., Fernández, G., Roozendaal, B., 2014. How the 
amygdala affects emotional memory by altering brain network properties. Neurobiol Learn Mem 
112, 2-16. 
 
 
33 
Hernandez, A., Burton, A.C., O’Donnell, P., Schoenbaum, G., Roesch, M.R., 2015. Altered basolateral 
amygdala encoding in an animal model of schizophrenia. J Neurosci 35 (16), 6394-6400. 
Hetem, L.A., Danion, J.M., Diemunsch, P., Brandt, C., 2000. Effects of subanesthetic dose of ketamine 
on memory and conscious awareness in healthy volunteers. Psychopharmacology 152 (3), 283-288. 
Hirota, K., Sikand K.S., Lambert, D.G., 1999. Interaction of ketamine with mu2 opioid receptors in SH-
SY5Y human neuroblastoma cells. J Anesth 13, 107-109. 
Honey, R.A.E., Honey, G.D., O’Loughlin, C., Sharar, S.R., Kumaran, D., Bullmore, E.T., Menon, D.K., 
Donovan, T., Lupson, V.C., Bisbrown-Chippendale, R., Fletcher, P.C., 2004. Acute ketamine 
administartion alters the brain responses to executive demands in a verbal working memory task: an 
FMRI study. Neuropsychopharmacology 29 (6), 1203-1214. 
Honey, G.D., Honey, R.A., Sharar, S.R., Turner, D.C., Pomarol-Clotet, E., Kumaran, D., Simons, J.S., Hu, 
X., Rugg, M.D., Bullmore, E.T., 2005. Impairment of specific episodic memory processes by sub-
psychotic doses of ketamine: the effects of levels of processing at encoding and of the subsequent 
retrieval task. Psychopharmacology 181 (3), 445-457. 
Honey, G.D., Honey, R.A.E,, O’Loughlin, C.O., Sharar, S.R., Kumaran, D., Suckling, J., Menon, D.K., 
Sleator, C., Bullmore, E.T., Fletcher, P.C., 2013. Ketamine disrupts frontal and hippocampal 
contribution to encoding and retrieval of episodic memory: an fMRI study. Cereb Cortex 15 (6), 749-
759. 
Horan, W.P., Green, M.F., Kring, A.M., Nuechterlein, K.H., 2006. Does anhedonia in schizophrenia 
reflect faulty memory for subjectively experienced emotions? Journal Abnorm Psychol 115 (3), 496-
508.  
Jentsch, J.D., Roth, R.H., 1999. The neuropsychopharmacology of phencyclidine: from NMDA 
receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20 
(3), 201-225. 
Kilpatrick, L., Cahill, L., 2003. Amygdala modulation of parahippocampal and frontal regions during 
emotionally influenced memory storage. Neuroimage 20 (4), 2091-2099.  
Kober, H., Barrett, L.F., Joseph, J., Bliss-Moreau, E., Lindquist, K., Wager, T.D., 2008. Functional 
grouping and cortical-subcortical interactions in emotion: a meta-analysis of neuroimaging studies. 
Neuroimage 42 (2), 998-1031. 
Köhler, S., Black, S., Sinden, M., Szekely, C., Kidron, D., Parker, J., Foster, J., Moscovitch, M., Wincour, 
G., Szalai, J., 1998. Memory impairments associated with hippocampal versus parahippocampal-
gyrus atrophy: an MR volumetry study in Alzheimer’s disease. Neuropsychologia 36 (9), 901-914. 
 
 
34 
Kienast, T., Hariri, A.R., Schlagenhauf, F., Wrase, J., Sterzer, P., Buchholz, H.G., Smolka, M.N., 
Gründer, G., Cumming, P., Kumakura, Y., 2008. Dopamine in amygdala gates limbic processing of 
aversive stimuli in humans. Nat Neurosci 11 (12), 1381-1382. 
Kim, H., 2011. Neural activity that predicts subsequent memory and forgetting: a meta-analysis of 74 
fMRI studies. Neuroimage 54 (3), 2446-2461. 
Kring, A.M., Moran, E.K., 2008. Emotional response deficits in schizophrenia: insights from affective 
science. Schizophr Bull 34 (5), 819-834. 
Krystal, J.H., D’Souza, D.C., Mathalon, D., Perry, E., Belger, A., Hoffman, R., 2003. NMDA receptor 
antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in 
medication development. Psychopharmacology 169 (3-4), 215-233.  
Krystal, J.H., Karper, L.P., Seibyl, J.P., Freeman, G.K., Delaney, R., Bremner, J.D., Heninger, G.R., 
Bowers, M.B., Charney, D.S., 1994. Subanesthetic effects of the noncompetitive NMDA antagonist, 
ketamine, in humans. sychotomimetic, perceptual, cognitive and neuroendocrine responses. Arch 
Gen Psychiatry 51 (3), 199-214.  
LaBar, K.S., Cabeza, R., 2006. Cognitive neuroscience of emotional memory. Nat Revi Neurosci 7 (1), 
54-64. 
Lakis, N., Jiménez, J.A., Mancini-Marïe, A., Stip, E., Lavoie, M.E., Mendrek, A., 2011. Neural correlates 
of emotional recognition memory in schizophrenia: effects of valence and arousal. Psychiatry Res 
194 (3), 245-256. 
Lang, P.J., Bradley, M.M., Cuthbert, B.N., 2008. International affective picture system (IAPS): 
Affective ratings of pictures and instruction manual. Technical report A-8. 
Lehrl, S., 2005. Mehrfachwahl-Wortschatz-Intelligenztest MWT-B. Balingen: Spitta Verlag Lepage, 
M., Habib, R., Tulving, E., 1998. Hippocampal PET activations of memory encoding and retrieval: the 
HIPER model. Hippocampus 8 (4), 313-322.  
Marwick, K., Hall, J., 2008. Social cognition in schizophrenia: a review of face processing. Br Med Bul 
88 (1), 43-58. 
Mason, O.J., Morgan, C.J.M., Stefanovic, A., Curran, H.V., 2008. The Psychotomimetic States 
Inventory (PSI):Measuring psychotic-type experiences from ketamine and cannabis. Schizophr Res 
103 (1-3), 138-142. 
Masneuf , S., Lowery-Gionta, E., Colacicco, G., Pleil, K.E., Li, C., Crowley, N., Flynn, S., Holmes, A., 
Kash, T., 2014. Glutamatergic mechanisms associated with stress-induced amygdala excitability and 
anxiety-related behaviors. Neuropharmacol 85, 190-197.  
McCleery, A., Lee, J., Joshi, A., Wynn, J.K., Hellemann, G.S., Green, M.F., 2015. Meta-analysis of face 
processing event-related potentials in schizophrenia. Biol Psychiatry 77 (2), 116-126. 
 
 
35 
McGaugh, J.L., 2004. The amygdala modulates the consolidation of memories of emotionally 
arousing experiences. Annu Rev Neurosci 27, 1-28. 
Mc Laren, D.G., Ries, M.L., Johnson, S.C., 2012. A generalized form of context-dependent 
psychopysiological interactions (gPPI): a comparison to standard approaches. Neuroimage 61 (4), 
1277-1286.  
Meador-Woodruff, J.H., Haroutunian, V., Powchik, P., Davidson, M., Davis, K.L., Watson, S.J., 1997. 
Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex: focal 
abnormalities in orbitofrontal cortex in schizophrenia. Arch Gen Psychiatry 54 (12), 1089-1095. 
Mesholam-Gately, R.I., Giuliano, A.J., Goff, K.P., Faraone, S.V., Seidman, L.J., 2009. Neurocognition in 
first-episode schizoprenia: a meta-analytic review. Neuropsychology 23 (3), 315-336. 
Morgan, C.J., Curran, H.V., 2006. Acute and chronic effects of ketamine upon human memory: a 
review. Psychopharmacology 188 (4), 408-424. 
Murty, V.P., Ritchey, M., Adcock, R.A., LaBar, K.S., 2010. fMRI studies of successful emotional 
memory encoding: A quantitative meta-analysis. Neuropsychologia 48 (12), 3459-3469. 
Newcomer, J.W., Farber, N.B., Jevtovic-Todorovic, V., Selke, G., Melson, A.K., Hershey, T., 1999. 
Ketamine-induced NMDA receptor hypofunctioning as a model of memory impairment and 
psychosis. Neuropsychopharmacol 20 (2), 106-118.  
Newcomer, J.W., Farber, N.B., Olney, J.W., 2000. NMDA receptor function, memory and brain aging. 
Dialogues Clin Neurosci 2 (3), 219-232. 
O’Driscoll, C., Laing, J., Mason, O., 2014. Cognitive emotion regulation strategies, alexithymia and 
dissociation in schizophrenia, a review and meta-analysis. Clin Psychol Rev 34 (6), 482-495. 
Pankow, A., Friedel, E., Sterzer, P., Seiferth, N., Walter, H., Heinz, A., Schlagenhauf, F., 2013. Altered 
amygdala activation in schizophrenia patients during emotion processing. Schizophr Res 150 (1), 
101-106. 
Pelletier, J.G., Likhtik, E., Filali, M., Pare, D., 2005. Lasting increases in basolateral amygdala activity 
after emotional arousal: implications for facilitated consolidation of emotional memories. Learn 
Mem 12 (2), 96-102. 
Phan, K.L., Taylor, S.F., Welsh, R.C., Decker, L.R., Noll, D.C., Nichols, T.E., Britton, J.C., Liberzon, I., 
2003. Activation of the medial prefrontal cortex and extended amygdala by individual ratings of 
emotional arousal: a fMRI study. Biol Psychiatry 53 (3), 211-215. 
Phan, K.L., Wager, T., Taylor, S.F., Liberzon, I., 2002. Functional Neuroanatomy of Emotion: A Meta-
Analysis of Emotion Activation Studies in PET and fMRI. Neuroimage 16 (2), 331-348.  
Preston, A.R., Eichenbaum, H., 2013. Interplay of hippocampus and prefrontal cortex in memory. 
Curr Biol 23 (17), 763-773.  
 
 
36 
Puma, C., Baudoin, C., Bizot, J.C., 1998. Effects of intraseptal infusions of N-methyl-D-aspartate 
receptor ligands on memory in an object recognition task in rats. Neurosci Lett 244 (2), 97-100.  
Rasch, B., Spalek, K., Buholzer, S., Luechinger, R., Boesiger, P., Papassotiropoulos, A., de Quervain, D-
F. 2009. A genetic variation of the noradrenergic system is related to differential amygdala activation 
during encoding of emotional memories. Proc Natl Acad Sci USA 106 (45), 19191-19196. 
Rasetti, R., Mattay, V.S., White, M.G., Sambataro, F., Podell, J.E., Zoltick, B., Chen, Q., Berman, K.F., 
Callicott, J.H., Weinberger, D.R., 2014. Altered hippocampal-parahippocampal function during 
stimulus encoding: a potential indicator of genetic liability for schizophrenia. JAMA psychiatry 71 (3), 
236-247. 
Reichenberg, A., Harvey, P.D., 2007. Neuropsychological impairments in schizophrenia: integration 
of performance-based and brain imaging findings. Psychol Bull 133 (5), 833-858. 
Richardson, M.P., Strange, B.A., Dolan, R.J., 2004. Encoding of emotional memories depends on 
amygdala and hippocampus and their inetractions. Nat Neurosci 7 (3), 278-285.  
Riedel, G., Platt, B., Micheau, J., 2003. Glutamate receptor function in learning and memory. Behav 
Brain Res 140 (1), 1-47.  
Rolls, E.T., Everitt, B., Roberts, A., 1996. The orbitofrontal cortex. Philos Trans R Soc Lond B Biol Sci 
351, 1433-1444. 
Savla, G.N., Vella, L., Armstrong, C.C., Penn, D.L., Twamley, E.W., 2013. Deficits in domains of social 
cognition in schizophrenia: a meta-analysis of empirical evidence. Schizophr Bull 39 (5), 979-992.  
Scheidegger, M., Henning, A., Walter, M., Boeker, H., Weigand, A., Seifritz, E., Grimm, S., 2016. 
Effects of ketamine on cognition-emotion interaction in the brain. Neuroimage 124 (Pt A), 8-15. 
Schlichting, M.L., Preston, A.R., 2015. Hippocampal-medial prefrontal circuit supports memory 
updating during learning and post-encoding rest. Neurobiol Learn Mem. 
doi:10.1016/j.nlm.2015.11.005. [Epub ahead of print] 
Schmechtig, A., Lees, J., Perkins, A., Altavilla, A., Craig, K., Dawson, G., Deakin, J.W., Dourish, C., 
Evans, L.H., Koychev, I., 2013. The effects of ketamine and risperidone on eye movement control in 
healthy volunteers. Transl Psychiatry 3, e334. 
Schmidt, A., Kometer, M., Bachmann, R., Seifritz, E., Vollenweider, F., 2013. The NMDA antagonist 
ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of 
emotional face expressions. Psychopharmacology 225 (1), 227-239.  
Schoenbaum, G., Takahashi, Y., Liu, T.L., McDannald, M.A., 2011. Does the orbitofrontal cortex signal 
value? Ann N Y Acad Sci 1239 (1), 87-99. 
Schon, K., Hasselmo, M.E., LoPresti, M.L., Tricarico, M.D., Stern, C.E., 2004. Persistence of 
parahippocampal representation in the absence of stimulus input enhances long-term encoding: a 
 
 
37 
functional magnetic resonance imaging study of subsequent memory after a delayed match-to-
sample task. J Neurosi 24 (49), 11088-11097. 
Steffens, M., Becker, B., Neumann, C., Kasparbauer, A.M., Meyhoefer, I., Weber, B., Mehta, M.A., 
Hurlemann, R., Ettinger, U., 2016. Effects of ketamine on brain function during smooth pursuit eye 
movements. Hum Brain Mapp 37 (11), 4047-4060. 
Stone, J.M., 2009. Imaging the glutamate system in humans: relevance to drug discovery for 
schizophrenia. Curr Pharm Des 15 (22), 2594-2602. 
Striepens, N., Scheele, D., Kendrick, K.M., Becker, B., Schäfer, L., Schwalba, K., Reul, J., Maier, W., 
Hurlemann, R., 2012. Oxytocin facilitates protective responses to aversive social stimuli in males. 
Proc Natl Acad Sci USA 109 (44), 18144-18149. 
Stuber, G.D., Sparta, D.R., Stamatakis, A.M., van Leuwen, W.A., Hardjoprajitno, J.E., Cho, S, Tye, 
K.M., Kempadoo, K.A., Zhang, F., Deisseroth, K., Bonci, A., 2011. Excitatory transmission from the 
amygdala to nucleus accumbens facilitates rewrad seeking. Nature 475 (7356), 377-380. 
Taylor, S.F., Liberzon, I., Decker, L.R., Koeppe, R.A., 2002. A functional anatomic study of emotion in 
schizophrenia. Schizophr Res 58 (2-3), 159-172. 
Taylor, S.F., Kang, J., Brege, I.S., Tso, I.F., Hosanagar, A., Johnson, T.D., 2012. Meta-analysis of 
functional neuroimaging studies of emotion perception and experience in schizophrenia. Biol 
Psychiatry 71 (2), 136-145.  
Thermenos, H.W., Seidman, L.J., Poldrack, R.A., Peace, N.K., Koch, J.K., Faraone, S.V., Tsuang, M.T., 
2007. Elaborative verbal encoding and altered anterior parahippocampal activation in adolescents 
and young adults at genetic risk for schizophrenia using FMRI. Biol Psychiatry 61 (4), 564-574. 
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, 
B., Joliot, M., 2002. Automated anatomical labeling of activations in SPM using a macroscopic 
anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15 (1), 273-289. 
Van Kesteren, M.T., Ruiter, D.J., Fernandez, G., Henson, R.N., 2012. How schema and novelty 
augment memory formation. Trends Neurosci 35 (4), 211-219.  
Vieira, P.A., Corches, A., Lovelace, J.W., Westbrook, K.B., Mendoza, M., Korzus., 2015. Prefrontal 
NMDA receptors expressed in excitatory neurons control fear discrimination and fear extinction. 
Neurobiol Learn Mem 119, 52-62.  
Walter ,M., Li, S., Demenescu, L.R., 2014. Multistage drug effects of ketamine in the treatment of 
major depression. Eur Arch Psychiatry Clin Neurosci 264  Suppl (1), 55-65.  
Wassum, K.M., Izquierdo, A., 2015. The basolateral amygdala in reward learning and addiction. 
Neurosci Biobehav Rev 57, 271-283. 
 
 
38 
Wong, J.J., O’Daly, O., Mehta, M.A., Young, A.H., Stone, J.M., 2016. Ketamine modulates subgenual 
cingulate connectivity with the memory-related neural circuits – a mechanism of relevance to 
resistant depression? PeerJ 4, e1710. 
Woo, C.W., Krishnan, A., Wager, T.D., 2014. Cluster-extent based thresholding in fMRI analyses: 
pitfalls and recommendations. Neuroimage 91, 412-419. 
Zarate, C.A., Singh, J.B., Carlson, P.J., Brutsche, N.E., Ameli, R., Luckenbaugh, D.A., Charney, D.S., 
Manji, H.K., 2006. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant 
major depression. Arch Gen Psychiatry 63 (8), 856-864.  
Zilverstand, A., Parvaz, M.A., Goldstein, R.Z., 2016. Neuroimaging cognitive reappraisal in clinical 
populations to define neural targets for enhancing emotion regulation. A systematic review. 
Neuroimage. doi: 10.1016/j.neuroimage.2016.06.009. [Epub ahead of print] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Highlights 
 Ketamine suppresses parahippocampal and prefrontal activity during encoding. 
 Amygdala and orbitofrontal activity is increased for negative stimuli by ketamine. 
 Ketamine generally increases medial prefrontal-parahippocampal coupling. 
 The general and emotion-specific effects overlap with alterations in 
schizophrenia. 
 
 
 
